Berlin \u2014 The Berlin-based company Selfapy, which offers people with mental illnesses effec\u00adtive help in the form of digi\u00adtal health appli\u00adca\u00adti\u00adons, has gained a strong part\u00adner in Medice Arznei\u00admit\u00adtel as an inves\u00adtor. The tran\u00adsac\u00adtion was supported by the invest\u00adment bank Bryan, Garnier & Co. On Decem\u00adber 23, 2022, a finan\u00adcing round of 7 million euros was nota\u00adri\u00adzed in Berlin. Leading the pack was Medice Arznei\u00admit\u00adtel, a family-owned phar\u00admaceu\u00adti\u00adcal company focu\u00adsed on the treat\u00adment of ADHD. All exis\u00adting inves\u00adtors were also invol\u00adved, inclu\u00adding the health\u00adcare inves\u00adtor SHS, Think.Health Ventures, IBB Ventures and HTGF.<\/p>\n
7 million for further growth in Germany and Europe A further part of the capi\u00adtal is to be used for market entry in other Euro\u00adpean countries:<\/p>\n \u201cWe see great poten\u00adtial for digi\u00adtal thera\u00adpies in the area of mental illness, both in Germany and inter\u00adna\u00adtio\u00adnally. With five comple\u00adted RCT studies and a broad user base in Germany, we are well on our way to expand our offe\u00adring to other indi\u00adca\u00adti\u00adons and into other markets,\u201d Adham Kassab, Co-CEO of Selfapy<\/p>\n \u201cSelfa\u00adpy\u2019s strong perfor\u00admance over the past few years speaks for itself. Digi\u00adtal health appli\u00adca\u00adti\u00adons will conti\u00adnue to gain importance in the coming years. We conti\u00adnue to see a lot of growth poten\u00adtial here and look forward to accom\u00adpany\u00ading Selfapy on this jour\u00adney,\u201d Dr. Richard Ammer, CEO of Medice. \u2014 Today, the MEDICE Group is one of the most successful owner-mana\u00adged family compa\u00adnies in the German phar\u00admaceu\u00adti\u00adcal indus\u00adtry, with more than 1,000 employees and annual sales of over 300 million EURO in around 50 markets worldwide.<\/p>\n
\n<\/strong>
\n\u201cThe funding round is an important mile\u00adstone and a confir\u00adma\u00adtion of confi\u00addence in the success of Selfapy,\u201d Nora Blum, Co-CEO and Foun\u00adder of Selfapy. The capi\u00adtal provi\u00added is to be used for the deve\u00adlo\u00adp\u00adment of further digi\u00adtal health appli\u00adca\u00adti\u00adons for various mental disor\u00adders and for growth in the German market. More doctors and psycho\u00adthe\u00adra\u00adpists can now be infor\u00admed by Selfapy about the bene\u00adfits of DiGA and prescribe Selfa\u00adpy\u2019s therapy cour\u00adses to their mentally ill patients.<\/p>\n